Scientific archive
Conference materials and company-sponsored analyses can communicate emerging data quickly. Peer review, study design, sample size, prespecification, missing data and independent replication all affect how evidence should be interpreted.
Bezisterim-associated anti-inflammatory epigenetic modulations of age acceleration and cognition in Alzheimer’s diseaseBezisterim modulates age-accelerating epigenetics in genes associated with sustaining inflammationEpigenetic modulation of age acceleration and Alzheimer’s disease genesReading et al., Frontiers in Neuroscience (2025)Bezisterim decreases biological age acceleration in Alzheimer’s diseaseBezisterim epigenetic effects on aging and neurodegenerationCTAD 2023 presentationAAIC — Alzheimer’s Phase 2 epigenetics dataAAN — Alzheimer’s study multi-modal analysesAAN — clinical outcomes encore posterAAN — safety, tolerability and efficacy of NE3107AASLD — BIV201 Phase 2b safetyAD/PD — effect of NE3107 on levodopa pharmacokineticsAD/PD — safety, tolerability and efficacy of NE3107ADA — Phase 3 Alzheimer’s study posterADPD — Phase 2a non-motor symptom scale presentationADPD — Phase 3 Alzheimer’s studyATMRD — Phase 2 Parkinson’s motor and non-motor outcomesATMRD — Phase 2 Parkinson’s protocol designEASL — BIV201 Phase 2b studyIAPRD — NE3107 in Parkinson’s diseaseMDS — Parkinson’s Phase 2 safety and pharmacokineticsMDS — Parkinson’s Phase 2 efficacyADA — Phase 3 Alzheimer’s study slide deckANA — Phase 3 Alzheimer’s study posterAPDDS — Phase 2 Parkinson’s oral presentationAPDDS — Phase 2 Parkinson’s posterARDD 2024 presentationCTAD 2022 biomarkers posterCTAD 2022 neuroimaging presentationCTAD 2022 clinical outcomes posterIAPRD 2024 Phase 2a non-motor symptom presentationMDS marmoset study oral deckMDS marmoset study posterAlzheimer’s depression and multi-modal outcomes slide deckSOBP — Alzheimer’s depression and multi-modal outcomes
Evidence note
A publication or conference presentation does not mean an investigational candidate has been shown safe or effective, and it does not indicate regulatory approval. Readers should review methods, limitations and the totality of evidence.
Evidence and compliance note
Development-stage information can change. Investigational candidates are not approved, and safety and efficacy have not been established. Review source documents and current regulatory disclosures.
